Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.
The clinical course of 10 liver transplant recipients who had hepatitis B virus (HBV) and five recipients with HBV and D (delta) infection before transplantation is described. Six patients who underwent eight transplants died. The estimated one and two year survival rates in patients with HBV only before transplantation were 74% and 67% respectively. The estimated one and two year survival in patients with HBV and HDV infection beforehand was 100%. Graft infection by HBV occurred in 8 of 10 patients infected with HBV only; and in 4 of 5 patients with previous HBV and HDV infection. There was a widely variable time from transplantation to the appearance of HBV markers in liver or serum, ranging from 6-331 days. Hepatitis D antigen (HDAg) appeared in three grafts very rapidly after transplantation at 4, 8, and 37 days respectively. Graft infection by HBV was accompanied by significant liver injury in six allografts in five recipients. In particular, there was a striking morphological appearance in five infected livers in which the hepatocytes became progressively enlarged and distorted as they accumulated huge amounts of hepatitis B surface and core antigens (HBsAg, HBcAg). These features were accompanied by pericellular fibrosis and cholestasis but little associated inflammation. This syndrome carried a poor prognosis. A gradual progression to cirrhosis occurred in one additional liver. Finally, recurrent HBV infection was a principal or a contributing factor in all deaths. The presence of HBcAg and inflammation in he native liver increased the risk of HBV induced tissue damaged in the graft whereas HDV infection in the host liver seemed to reduce the risk of significant HBV induced tissue damage in the allograft. These data suggest that post transplant HBV infection is accompanied by a variety of changes in the liver allograft, some of which are unique to the transplanted liver and may result in impaired allograft function.
Lucey
M R
MR
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0362, USA.
Graham
D M
DM
Martin
P
P
Di Bisceglie
A
A
Rosenthal
S
S
Waggoner
J G
JG
Merion
R M
RM
Campbell
D A
DA
Nostrant
T T
TT
Appelman
H D
HD
D000293:Adolescent; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D006511:Hepatitis B Antigens / Q000032:analysis; D006512:Hepatitis B Core Antigens / Q000032:analysis; D003699:Hepatitis D / Q000276:immunology* / Q000401:mortality; D006801:Humans; D008099:Liver / Q000276:immunology* / Q000473:pathology; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors
D006511:Hepatitis B Antigens; D006512:Hepatitis B Core Antigens